Jan 2016 $79 M No. 7 $50 to $250 million 20
Aprecia Pharmaceuticals Co: Raise no. 7, Jan 2016 × Investors in this round 20 investors had bought by the notice of Jan 28, 2016: 20 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $79 M of $84 M offered; $5 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $3,168,907
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Thomas Furniss · Executive Officer Donald Thomas Wetherhold · Executive Officer Michael Thomas Rolhfs · Executive Officer Robert Thomas Williford · Executive Officer E Thomas Arington · Director Etienne Thomas Perold · Director James Thomas Evans · Director Jonathan Thomas Leff · Director Lawrence Thomas Glassmann · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round MTS Securities, LLC (CRD 104059) · New York, New York Sold in CA, MA, MD, NY, OH Signed by Donald Wetherhold, Ceo. Source: SEC Form D, newest notice filed Jan 28, 2016. Read the notice at the SEC .
equity SEC Aug 2015 $39 M No. 6 $10 to $50 million 8
Aprecia Pharmaceuticals Co: Raise no. 6, Aug 2015 × Investors in this round 8 investors had bought by the notice of Aug 31, 2015: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $39 M of $52 M offered; $13 M still to sell
Smallest investment taken $1
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Thomas Furniss · Executive Officer Donald Thomas Wetherhold · Executive Officer Michael Thomas Rohlfs · Executive Officer Robert Thomas Williford · Executive Officer E Thomas Arington · Director Etienne Thomas Perold · Director James Thomas Evans · Director Lawrence Thomas Glassmann · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Donald Wetherhold, Ceo. Source: SEC Form D, newest notice filed Aug 31, 2015. Read the notice at the SEC .
debt, options SEC Nov 2013 $15 M No. 5 $10 to $50 million 1
Aprecia Pharmaceuticals Co: Raise no. 5, Nov 2013 × Investors in this round 1 investor had bought by the notice of Dec 10, 2013: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $15 M of $36 M offered; $21 M still to sell
Smallest investment taken $1
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David A. Furniss · Executive Officer Donald A. Wetherhold · Executive Officer Michael A. Rohlfs · Executive Officer Robert A. Williford · Executive Officer E Thomas Arington · Director Etienne A. Perold · Director Lawrence Thomas Glassmann · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Donald Wetherhold, Ceo. Source: SEC Form D and 1 amendment, newest notice filed Dec 10, 2013. Read the notice at the SEC .
debt, options SEC Nov 2012 $4 M No. 4 $2 to $10 million 1
Aprecia Pharmaceuticals Co: Raise no. 4, Nov 2012 × Investors in this round 1 investor had bought by the notice of Nov 19, 2012: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $9 M offered; $5 M still to sell
Smallest investment taken $2
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice E Thomas Arington · Executive Officer, Director Glenn S. Vraniak · Executive Officer Lawrence Thomas Glassmann · Executive Officer, Director Michael S. King · Executive Officer Etienne A. Perold · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Michael King, Cfo. Source: SEC Form D, newest notice filed Nov 19, 2012. Read the notice at the SEC .
debt, options SEC Oct 2011 $26 M No. 3 $10 to $50 million 1
Aprecia Pharmaceuticals Co: Raise no. 3, Oct 2011 × Investors in this round 1 investor had bought by the notice of Nov 4, 2011: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $26 M of $26 M offered
Smallest investment taken $25,725,261
What was sold equity
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Don S. Wetherhold · Executive Officer Donald C. Monkhouse · Executive Officer Etienne A. Perold · Executive Officer, Director Glenn S. Vraniak · Executive Officer Michael C. King · Executive Officer E Thomas Arington · Director Lawrence C. Glassmann · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Michael King, Cfo. Source: SEC Form D, newest notice filed Nov 4, 2011. Read the notice at the SEC .
equity SEC Oct 2010 $4 M No. 2 $2 to $10 million 1
Aprecia Pharmaceuticals Co: Raise no. 2, Oct 2010 × Investors in this round 1 investor had bought by the notice of Dec 20, 2010: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $5 M offered; $1 M still to sell
Smallest investment taken $105,000
What was sold equity
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Donald Monkhouse · Executive Officer, Director Etienne Perold · Executive Officer, Director Henry Surprenant · Executive Officer Jaedeok Yoo · Executive Officer Michael King · Executive Officer Joseph Highland · Director Lawrence Glassmann · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Donald Monkhouse, President. Source: SEC Form D, newest notice filed Dec 20, 2010. Read the notice at the SEC .
equity SEC Dec 2009 $6 M No. 1 $2 to $10 million 1
Aprecia Pharmaceuticals Co: Raise no. 1, Dec 2009 × Investors in this round 1 investor had bought by the notice of Jan 25, 2010: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken $2,500,000
What was sold equity
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Donald Monkhouse · Executive Officer, Director Etienne Perold · Executive Officer, Director Henry Surprenant · Executive Officer Jaedeok Yoo · Executive Officer Michael King · Executive Officer Joseph Highland · Director Lawrence Glassmann · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Donald Charles Monkhouse, President and CSO. Source: SEC Form D and 1 amendment, newest notice filed Jan 25, 2010. Read the notice at the SEC .
equity SEC